Social media

1 in 5 people will develop heart failure in their lifetime. ICON recognises the importance to raise global awareness of heart failure risk factors such as hypertension, obesity, diabetes and coronary heart disease. Dis...

1 in 5 people will develop heart failure in their lifetime. ICON recognises the importance to raise global awareness of heart failure risk factors such as hypertension, obesity, diabetes and coronary heart disease. Dis...

Next week ICON Biotech sponsors #OCTWestCoast! Drop by booth \#79 to speak with our experts, including Travis Caudill VP who will be giving a special featured presentation and appearing on a panel to discuss the latest A...

Next week ICON Biotech sponsors #OCTWestCoast! Drop by booth #79 to speak with our experts, including Travis Caudill VP who will be giving a special featured presentation and appearing on a panel to discuss the latest AI...

ICON is proud to support Heart Failure Awareness Week. As a global leader in cardiovascular trials, we remain committed to raising awareness and advancing better, safer and more cost‑effective therapies for people living...

ICON is a proud sponsor of this year’s #ISCR Annual Conference, taking place in New Dehli from 13 – 14 February. Visit the ICON team at booth #G-11 to learn about our high-quality, global services and solutions to suppor...

ICON is a proud sponsor of this year’s #ISCR Annual Conference, taking place in New Dehli from 13 – 14 February. Visit the ICON team at booth #G-11 to learn about our high-quality, global services and solutions to suppor...

Next week ICON Biotech sponsors #OCTWestCoast. Drop in and speak to our experts at booth \#79. Don’t miss out on the “How far can AI take us” panel discussion which features ICON’s Travis Caudill on 11 February at 12 pm....

There is great excitement following the announcements by the FDA and EMA around streamlining the biosimilar trial process. They promise to reduce the burden on developers and therefore increase the number of more afford...

2025 has seen both the EMA and the FDA publish new position papers and opinions on streamlining the trial process for biosimilars. On the surface, reducing reliance on comparative efficacy trials has the potential to sav...

In oncology, a single biomarker usually is not enough to provide useful information about a patient’s cancer or response to treatment, and the relationships between individual biomarkers can be difficult to establish or ...

ICON is a proud supporter of #WorldCancerDay. As a recognised leader in conducting complex early phase to global oncology #clinical trials, we are working with our clients to accelerate the development of drugs and devic...